Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas
X.WeiJ.et al (2023)
The potential for glutathione to minimize or reduce free radicals is apparent from the reported changes in glutathione status after exercise
J Appl Physiol 103:17361743 Derave W, De Courten B, Baba SP (2019) An update on carnosine and anserine research
Lilly has also reported Phase 3 diabetes data showing A1C reduction and weight loss in adults with type 2 diabetes
What side effects should I expect from semaglutide therapy